These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 20446017)

  • 1. Expression of signal transducer and activator of transcription 3 (STAT3) in primary central nervous system diffuse large B-cell lymphoma: a retrospective analysis of 17 cases.
    Vajpayee N; Hussain J; Tolocica I; Hutchison RE; Gajra A
    J Neurooncol; 2010 Nov; 100(2):249-53. PubMed ID: 20446017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.
    Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
    Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated B-cell immunophenotype might be associated with poor prognosis of primary central nervous system lymphomas.
    Bhagavathi S; Sharathkumar A; Hunter S; Sung L; Kanhere R; Venturina MD; Wilson JD
    Clin Neuropathol; 2008; 27(1):13-20. PubMed ID: 18257470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma.
    Ok CY; Chen J; Xu-Monette ZY; Tzankov A; Manyam GC; Li L; Visco C; Montes-Moreno S; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Zhao X; Ponzoni M; Ferreri AJ; Bertoni F; Farnen JP; Møller MB; Piris MA; Winter JN; Medeiros LJ; Young KH
    Clin Cancer Res; 2014 Oct; 20(19):5113-23. PubMed ID: 25124685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCL2 expression is associated with a poor prognosis independent of cellular origin in primary central nervous system diffuse large B-cell lymphoma.
    Makino K; Nakamura H; Shinojima N; Kuroda JI; Yano S; Mikami Y; Mukasa A
    J Neurooncol; 2018 Oct; 140(1):115-121. PubMed ID: 29968039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma.
    Lam LT; Wright G; Davis RE; Lenz G; Farinha P; Dang L; Chan JW; Rosenwald A; Gascoyne RD; Staudt LM
    Blood; 2008 Apr; 111(7):3701-13. PubMed ID: 18160665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SHP-1 expression in primary central nervous system B-cell lymphomas in immunocompetent patients reflects maturation stage of normal B cell counterparts.
    Sugita Y; Tokunaga O; Nakashima A; Shigemori M
    Pathol Int; 2004 Sep; 54(9):659-66. PubMed ID: 15363033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin.
    Lin CH; Kuo KT; Chuang SS; Kuo SH; Chang JH; Chang KC; Hsu HC; Tien HF; Cheng AL
    Clin Cancer Res; 2006 Feb; 12(4):1152-6. PubMed ID: 16489068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart.
    Chang C; Lin CH; Cheng AL; Medeiros LJ; Chang KC
    Histopathology; 2015 Nov; 67(5):625-35. PubMed ID: 25829022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A clinicopathological study of primary central nervous system lymphomas & their association with Epstein-Barr virus.
    Sharma MC; Gupta RK; Kaushal S; Suri V; Sarkar C; Singh M; Kale SS; Sahoo RK; Kumar L; Raina V
    Indian J Med Res; 2016 May; 143(5):605-15. PubMed ID: 27488004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Most primary central nervous system diffuse large B-cell lymphomas occurring in immunocompetent individuals belong to the nongerminal center subtype: a retrospective analysis of 31 cases.
    Hattab EM; Martin SE; Al-Khatib SM; Kupsky WJ; Vance GH; Stohler RA; Czader M; Al-Abbadi MA
    Mod Pathol; 2010 Feb; 23(2):235-43. PubMed ID: 19935644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical importance of Bcl-6-positive non-deep-site involvement in non-HIV-related primary central nervous system diffuse large B-cell lymphoma.
    Song MK; Chung JS; Joo YD; Lee SM; Oh SY; Shin DH; Yun EY; Kim SG; Seol YM; Shin HJ; Choi YJ; Cho GJ
    J Neurooncol; 2011 Sep; 104(3):825-31. PubMed ID: 21380743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative clinicopathological study of primary CNS diffuse large B-cell lymphoma and intravascular large B-cell lymphoma.
    Imai H; Shimada K; Shimada S; Abe M; Okamoto M; Kitamura K; Kinoshita T; Shiraishi T; Nakamura S
    Pathol Int; 2009 Jul; 59(7):431-7. PubMed ID: 19563405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases.
    Camilleri-Broët S; Crinière E; Broët P; Delwail V; Mokhtari K; Moreau A; Kujas M; Raphaël M; Iraqi W; Sautès-Fridman C; Colombat P; Hoang-Xuan K; Martin A
    Blood; 2006 Jan; 107(1):190-6. PubMed ID: 16150948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STAT3 Activation Is Associated with Interleukin-10 Expression and Survival in Primary Central Nervous System Lymphoma.
    Yang X; Wang Y; Sun X; Bai X; Cui Q; Zhu H; Qian J; Chen Y; Sun S; Ji N; Liu Y
    World Neurosurg; 2020 Feb; 134():e1077-e1084. PubMed ID: 31778838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of the immunohistochemical subtypes and prognosis of primary diffuse large B cell lymphoma of the central nervous system].
    Min M; Lin L; Bi CF; Wang XQ; Luo TY; Zhao S; Zhang WY; Liu WP
    Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):110-6. PubMed ID: 22780928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
    Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
    Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
    [No Abstract]   [Full Text] [Related]  

  • 18. Expression of immunoglobulin transcription factors in primary intraocular lymphoma and primary central nervous system lymphoma.
    Coupland SE; Loddenkemper C; Smith JR; Braziel RM; Charlotte F; Anagnostopoulos I; Stein H
    Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):3957-64. PubMed ID: 16249468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunophenotyping of diffuse large B-cell lymphoma (DLBCL) defines multiple sub-groups of germinal centre-like tumours displaying different survival characteristics.
    Anderson JJ; Fordham S; Overman L; Dignum H; Wood K; Proctor SJ; Crosier S; Angus B; Culpin RE; Mainou-Fowler T
    Int J Oncol; 2009 Nov; 35(5):961-71. PubMed ID: 19787248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals.
    Chang CC; Kampalath B; Schultz C; Bunyi-Teopengco E; Logan B; Eshoa C; Dincer AP; Perkins SL
    Arch Pathol Lab Med; 2003 Feb; 127(2):208-12. PubMed ID: 12562237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.